Creating cancer therapies based around natural killer cells could offer similar levels of efficacy to CAR-T therapies, but at around one hundredth of the cost.
Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, has secured £920,000 from the British government’s Innovate UK to create a safe, effective red
